<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ro">
	<id>https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=Entasis_Therapeutics_Hldgs_Inc</id>
	<title>Entasis Therapeutics Hldgs Inc - Revizia istoricului</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=Entasis_Therapeutics_Hldgs_Inc"/>
	<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=Entasis_Therapeutics_Hldgs_Inc&amp;action=history"/>
	<updated>2026-04-30T18:55:38Z</updated>
	<subtitle>Istoricul versiunilor pentru această pagină din wiki</subtitle>
	<generator>MediaWiki 1.39.2</generator>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=Entasis_Therapeutics_Hldgs_Inc&amp;diff=418691&amp;oldid=prev</id>
		<title>Admin: Pagină nouă: Pagina dedicata companiei Entasis Therapeutics Hldgs Inc listata cu simbolul US.ETTX  ==Descriere companie== Entasis Therapeutics Holdings Inc. (https://www.entasistx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibacterial products to treat infections caused by multi-drug resistant pathogens. Its lead product candidate is Sulbactam-durlobactam (SUL-DUR), which is an IV antibiotic with bro...</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=Entasis_Therapeutics_Hldgs_Inc&amp;diff=418691&amp;oldid=prev"/>
		<updated>2024-09-18T17:54:25Z</updated>

		<summary type="html">&lt;p&gt;Pagină nouă: Pagina dedicata companiei Entasis Therapeutics Hldgs Inc listata cu simbolul US.ETTX  ==Descriere companie== Entasis Therapeutics Holdings Inc. (https://www.entasistx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibacterial products to treat infections caused by multi-drug resistant pathogens. Its lead product candidate is Sulbactam-durlobactam (SUL-DUR), which is an IV antibiotic with bro...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Pagină nouă&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Pagina dedicata companiei Entasis Therapeutics Hldgs Inc listata cu simbolul US.ETTX&lt;br /&gt;
&lt;br /&gt;
==Descriere companie==&lt;br /&gt;
Entasis Therapeutics Holdings Inc. (https://www.entasistx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibacterial products to treat infections caused by multi-drug resistant pathogens. Its lead product candidate is Sulbactam-durlobactam (SUL-DUR), which is an IV antibiotic with broad spectrum b-lactamase coverage. The Company’s pipeline includes sulbactam-durlobactam (ETX2514SUL), zoliflodacin, ETX0282CPDP and ETX0462. ETX2514SUL is a fixed-dose combination with b-lactams. Zoliflodacin as a single dose, oral antibiotic monotherapy. ETX0282CPDP is an oral fixed-dose combination of ETX0282 with cefpodoxime proxetil. The pipeline includes programs for differentiated medicines to treat multidrug-resistant Gram-negative infections, such as Pseudomonas aeruginosa, Acinetobacter baumanii, carbapenem-resistant Enterobacteriaceae and Neisseria gonorrhoeae.&lt;br /&gt;
&lt;br /&gt;
==Grafic actiuni companie==&lt;br /&gt;
&amp;lt;iframe key=&amp;quot;tradeville&amp;quot; path=&amp;quot;graficSimbol/US.ETTX&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Ultimele stiri despre Entasis Therapeutics Hldgs Inc (US.ETTX)==&lt;br /&gt;
&amp;lt;dynamicpagelist&amp;gt;&lt;br /&gt;
category=US.ETTX&lt;br /&gt;
count=10&lt;br /&gt;
order=descending&lt;br /&gt;
addfirstcategorydate=false&lt;br /&gt;
&amp;lt;/dynamicpagelist&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Categorie:US.ETTX]][[Categorie:Stiri despre companii]]&lt;/div&gt;</summary>
		<author><name>Admin</name></author>
	</entry>
</feed>